13 results about "Addictive behavior" patented technology

This invention discloses a strain of *Bifidobacterium pseudosporidis*, its preparation method, and its application in the prevention and treatment of METH addiction. *Bifidobacterium pseudosporidis* was isolated from fecal samples of individuals with low levels of METH addiction, and its strain identity was confirmed after isolation, purification, and identification. A METH addiction model was constructed by gavage colonization of C57 mice with this strain, and addiction-related indicators were detected in the model mice. The results showed that compared with the addiction model mice without colonization of this strain, the conditioned place preference score of the colonized group was significantly reduced (P<0.05). This *Bifidobacterium pseudosporidis* has a significant effect on improving METH addictive behavior and can be used to prepare biological agents with preventive and / or therapeutic functions for METH addiction. This invention reveals that *Bifidobacterium pseudosporidis* has the advantages of high safety and strong targeting, and can achieve the prevention and intervention of METH addiction without complex treatment equipment, providing a novel biological treatment option for the clinical treatment of METH addiction.

A pathway planning apparatus includes a processor configured to plan a pathway for implanting an electrode lead into a brain of a patient, wherein the planned pathway satisfies the following condition: if the electrode lead is implanted into the brain of the patient according to the pathway, the electrode lead is capable of simultaneously making contact with an anterior limb of an internal capsule and a nucleus accumbens in one hemisphere of a brain of the patient. The pathway planned by the pathway planning apparatus enables the electrode lead to simultaneously deliver the electrical stimulation to the anterior limb of the internal capsule and the nucleus accumbens such that a combined electrical stimulation therapy is achieved, which has a better effect of treating diseases such as addictive behaviors, depressive disorders, and obsessive-compulsive disorders.

The invention discloses a living body screening method of a high-throughput addiction inhibitor, which comprises the following steps: acquiring addictive nematodes with a plurality of addiction behavioral phenotypes; applying different addiction inhibitors to the addictive nematodes; the screening of the addiction inhibitors is realized according to the inhibition efficacy of the addiction inhibitors on the addiction behavioral phenotypes of the addiction nematodes, and based on the steps, the drug screening of the addiction inhibitors can be realized through the inhibition efficacy of the addiction inhibitors on the addiction behavioral phenotypes of the addiction nematodes in a high-throughput manner. Compared with the prior art, the medicine screening method of a traditional cell function system is abandoned, and medicine screening is carried out on the living animal behavioristics level in a brand new mode. Meanwhile, the advantages of easiness in large-scale culture, abundant behavioral modes and the like of the nematodes are utilized, and compared with expensive mammal feeding and experimental operation for drug screening, the method has higher cost performance, practical operability and high throughput.

The invention relates to the technical field of biological medicine, in particular to application of quercetin in preparation of a medicine for treating or preventing methamphetamine addiction. The invention provides an application of quercetin in preparation of a medicine for treating or preventing methylamphetamine addiction. Through an METH (methylamphetamine) self-administration model, it is found that quercetin can significantly reduce the active nasal staking frequency and injection frequency of rats, it is proved that quercetin can significantly inhibit the rat addiction behavior to methylamphetamine, and the quercetin has a wide clinical application prospect.

The present disclosure is directed to a beverage composition comprising from a cannabis extract and a Hericium erinaceus extract. The present disclosure also relates to methods of reducing a withdrawal symptom and / or reducing an addictive behavior comprising administering a therapeutically effective amount of the aforementioned beverage composition to a subject having the withdrawal symptom and / or the addictive behavior, methods for treating alcoholism in a subject comprising administering a therapeutically effective amount of the aforementioned beverage composition to the subject, and method of producing altered perception and / or reduced stress while ameliorating a side effect of THC overconsumption in a subject comprising administering a therapeutically effective amount of the aforementioned beverage composition to the subject.

The invention discloses a short video anti-addiction method and a mobile terminal, and relates to the technical field of mobile terminal application control, and the method comprises the following steps: S1, detecting a continuous sliding operation state of a user in a short video application; s2, when it is detected that the continuous sliding operation state meets a preset condition, an anti-addiction intervention mechanism is triggered; s3, executing at least one of the following intervention modes: (1) randomly replacing a sliding operation of the user with a return operation; (2) the resistance of sliding operation is increased, and the sliding distance is prolonged; (3) switching the application interface into a black and white display mode; according to the method, the core addiction behavior of high-frequency sliding is detected in real time, the addiction chain can be broken earlier instead of depending on the accumulated time length, gesture replacement, resistance enhancement and black and white display are integrated into the normal operation process of a user, strong interference modes such as forced screen locking and popup shielding do not exist, and the user acceptability is high.

The presnt disclosure is directed to a beverage composition comprising from a cannabis extract and a Hericium erinaceus extract. The present disclosure also relates to methods of reducing a withdrawal symptom and / or reducing an addictive behavior comprising administering a therapeutically effective amount of the aforementioned beverage composition to a subject having the withdrawal symptom and / or the addictive behavior, methods for treating alcoholism in a subject comprising administering a therapeutically effective amount of the aforementioned beverage composition to the subject, and method of producing altered perception and / or reduced stress while ameliorating a side effect of THC overconsumption in a subject comprising administering a therapeutically effective amount of the aforementioned beverage composition to the subject.

The invention relates to the field of biological medicine, and discloses application of lncRNA Meg3 as a target spot in anti-addiction drugs. Through next-generation sequencing, it is found that lncRNA Meg3 in hippocampus tissues of oxycodone addiction mice is highly expressed, and m6A methylation is mediated by METTL3. SiRNA Meg3 is designed aiming at the target spot and is wrapped in lipid nanoparticles, and the oxycodone addiction behavior can be remarkably inhibited through nasal administration. The siRNA lipid particle has no addiction, has no influence on normal behaviors such as sweet water preference and the like, and has specificity. Experiments prove that the compound plays a role by blocking an ERK / MEK signal channel. The invention provides a new strategy for the development of anti-addiction drugs.

The invention relates to an addiction behavior monitoring system and method based on intelligent glasses, and the system comprises the intelligent glasses and a cloud server. The intelligent glasses are used for collecting a first person visual image of a user, starting continuous video recording to generate corresponding multi-modal feature data under the condition that a target terminal exists in the first person visual image, and uploading the multi-modal feature data to the cloud server; and the cloud server is used for receiving the multi-modal feature data, monitoring digital addiction behaviors of the user in a continuous time sequence according to the multi-modal feature data, and performing hierarchical intervention under the condition that the user has an addiction risk. Through the application, all-weather cross-platform accurate monitoring, early warning and graded intervention of the addiction risk by using the intelligent glasses are realized, the condition of the target terminal is identified firstly, then continuous video recording is started, low-power-consumption operation of the intelligent glasses is ensured, and the problem of how to improve the monitoring capability of the digital addiction risk of a user is solved.

The invention provides an EMDR theory-based addiction behavior long-acting intervention system and equipment, and relates to the technical field of artificial intelligence, the system comprises an evaluation module, a processing module, a generation module, a drilling module and an integration module, and a standard system for integrating a Fagger behavior model and an eye movement desensitization reprocessing therapy is constructed. And automatic generation and matching of healthy micro behaviors are realized based on an algorithm, so that the technical problems of weak motivation maintenance, difficult behavior conversion and high recurrence rate in the prior art are solved, and dual-path long-acting intervention from an emotion root to a behavior mode is realized.

The invention discloses a gene-coded opioid receptor fluorescent probe as well as a preparation method and application thereof, the opioid receptor fluorescent probe comprises fusion of a human Mu-chip receptor and a green fluorescent protein, and the amino acid sequence of the opioid receptor fluorescent probe is shown as SEQ ID NO.1. The opioid receptor fluorescent probe constructed by the invention has good membrane positioning capability, good fluorescence signal stability and specificity and large detection range; the compound shows specific response to opioid drugs and endogenous opioid peptides (such as beta-enkephalin and enkephalin) in HEK293T cells, the fluorescence intensity and the ligand concentration are dose-dependent, the compound can be blocked by an antagonist, and the compound has excellent selectivity and pharmacological characteristics. The probe constructed by the invention can be used for novel analgesic drug development, pain mechanism research and addiction behavior monitoring.

Provided herein is a method for weaning a subject suffering from a drug addiction or addictive behaviors involving opioid signaling by sequentially blocking peripheral and CNS opioid receptors and modulating opioid dependence.

The present invention discloses the use of ethyl pyruvate in the preparation of a drug for treating or preventing methamphetamine addiction. The present invention belongs to the field of pharmaceutical technology and provides the use of ethyl pyruvate in the preparation of a drug for treating or preventing methamphetamine addiction. Ethyl pyruvate inhibits the HMGB1-TLR4-MyD88-PI3K-AKT-NF-KB signaling pathway, reduces neuroinflammatory responses, and significantly reduces addictive behaviors and nerve damage caused by methamphetamine. This provides a new therapeutic strategy for the treatment of methamphetamine addiction and has broad clinical application prospects. Ethyl pyruvate has significant neuroprotective effects, can reduce nerve damage, and promote nerve repair.